{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:29Z","timestamp":1790806829406,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ophtha.2014.12.017","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T23:10:45Z","timestamp":1423869045000},"page":"1008-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":189,"title":["Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"122","author":[{"given":"Christopher K.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Baker","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.12.017_bib1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2014.12.017_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in\u00a0vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2014.12.017_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2014.12.017_bib4","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.12.017_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3928\/0191-3913-19970301-06","article-title":"Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome","volume":"34","author":"White","year":"1997","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ophtha.2014.12.017_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0002-9394(01)00956-4","article-title":"Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome","volume":"132","author":"Shalev","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib7","first-page":"81","article-title":"Clinical outcome of confluent laser photoablation for retinopathy of prematurity","volume":"6","author":"Fallaha","year":"2002","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2014.12.017_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/eye.2009.63","article-title":"Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years","volume":"24","author":"Yang","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2014.12.017_bib9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","article-title":"Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment","volume":"29","author":"Sanghi","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.12.017_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3928\/01913913-20100308-05","article-title":"Confluent laser photocoagulation for the treatment of retinopathy of prematurity","volume":"47","author":"Gonzalez","year":"2010","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ophtha.2014.12.017_bib11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib12","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.12.017_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2009.02.006","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study","volume":"148","author":"Bashshur","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.12.017_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00006982-200604000-00001","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.12.017_bib16","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.017_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"issue":"3 Suppl","key":"10.1016\/j.ophtha.2014.12.017_bib19","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.12.017_bib20","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2014.12.017_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jop.2011.0060","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","volume":"27","author":"Harder","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2014.12.017_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.017_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.12.017_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ajo.2010.10.007","article-title":"Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program report number 2","volume":"151","author":"Jalali","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2012.07.012","article-title":"Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation","volume":"155","author":"Sanghi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib28","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative G","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"7 Suppl","key":"10.1016\/j.ophtha.2014.12.017_bib29","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.12.017_bib30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0161-6420(01)00695-9","article-title":"Outcomes after laser therapy for threshold retinopathy of prematurity","volume":"108","author":"Foroozan","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.017_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone 1 retinopathy of prematurity","volume":"81","author":"O\u2019Keefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2014.12.017_bib32","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1136\/archdischild-2013-303933","article-title":"Management of retinopathy of prematurity","volume":"98","author":"Fleck","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.ophtha.2014.12.017_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.017_bib36","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.2004.045815","article-title":"Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months","volume":"89","author":"Sahni","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib38","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.82.11.1254","article-title":"Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser","volume":"82","author":"Pearce","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.12.017_bib39","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(98)99029-7","article-title":"A\u00a0comparison of laser photocoagulation with trans-scleral cryotherapy in the treatment of threshold retinopathy of prematurity","volume":"105","author":"Connolly","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.12.017_bib40","first-page":"454","article-title":"Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity","volume":"10","author":"McLoone","year":"2006","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2014.12.017_bib41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","journal-title":"Retina"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014011944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014011944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T14:36:10Z","timestamp":1651242970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014011944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0161642014011944"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725357810.793504433","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}